The in vivo toxicity reported for CC-88559 may be associated with these observed off-target effectsand would support a preference of the more selective GSPT1 degrader(CC-90009) in clinical trials for acute myeloid leukemia (AML)41,59 (in clinical trials #NCT02848001, #NCT04336982). The gene discussed is GSPT1; the disease is acute myeloid leukemia.